About Cytoskeleton-associated protein 5
Cytoskeleton-associated protein 5 (CKAP5) is a protein
from Homo sapiens identified by UniProt accession
Q14008, 2032 residues long.
MolForge cross-references it against 0 known binders and
83 disease associations.
Target properties
| Protein name | Cytoskeleton-associated protein 5 |
|---|
| UniProt accession | Q14008 |
|---|
| Gene | CKAP5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2032 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (83)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- ovarian cancer · score 0.23
- low grade glioma · score 0.23
- breast adenocarcinoma · score 0.23
- blood protein measurement · score 0.20
- thrombophilia due to thrombin defect · score 0.12
- congenital prothrombin deficiency · score 0.12
- prothrombin deficiency · score 0.12
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14008-F1 | alphafold | PREDICTED | 75.25 | — |
Amino-acid sequence (2032 residues)
MGDDSEWLKL PVDQKCEHKL WKARLSGYEE ALKIFQKIKD EKSPEWSKFL GLIKKFVTDS NAVVQLKGLE AALVYVENAH VAGKTTGEVV SGVVSKVFNQ PKAKAKELGI EICLMYIEIE KGEAVQEELL KGLDNKNPKI IVACIETLRK ALSEFGSKII LLKPIIKVLP KLFESREKAV RDEAKLIAVE IYRWIRDALR PPLQNINSVQ LKELEEEWVK LPTSAPRPTR FLRSQQELEA KLEQQQSAGG DAEGGGDDGD EVPQIDAYEL LEAVEILSKL PKDFYDKIEA KKWQERKEAL ESVEVLIKNP KLEAGDYADL VKALKKVVGK DTNVMLVALA AKCLTGLAVG LRKKFGQYAG HVVPTILEKF KEKKPQVVQA LQEAIDAIFL TTTLQNISED VLAVMDNKNP TIKQQTSLFI ARSFRHCTAS TLPKSLLKPF CAALLKHIND SAPEVRDAAF EALGTALKVV GEKAVNPFLA DVDKLKLDKI KECSEKVELI HGKKAGLAAD KKEFKPLPGR TAASGAAGDK DTKDISAPKP GPLKKAPAAK AGGPPKKGKP AAPGGAGNTG TKNKKGLETK EIVEPELSIE VCEEKASAVL PPTCIQLLDS SNWKERLACM EEFQKAVELM DRTEMPCQAL VRMLAKKPGW KETNFQVMQM KLHIVALIAQ KGNFSKTSAQ VVLDGLVDKI GDVKCGNNAK EAMTAIAEAC MLPWTAEQVV SMAFSQKNPK NQSETLNWLS NAIKEFGFSG LNVKAFISNV KTALAATNPA VRTAAITLLG VMYLYVGPSL RMFFEDEKPA LLSQIDAEFE KMQGQSPPAP TRGISKHSTS GTDEGEDGDE PDDGSNDVVD LLPRTEISDK ITSELVSKIG DKNWKIRKEG LDEVAGIIND AKFIQPNIGE LPTALKGRLN DSNKILVQQT LNILQQLAVA MGPNIKQHVK NLGIPIITVL GDSKNNVRAA ALATVNAWAE QTGMKEWLEG EDLSEELKKE NPFLRQELLG WLAEKLPTLR STPTDLILCV PHLYSCLEDR NGDVRKKAQD ALPFFMMHLG YEKMAKATGK LKPTSKDQVL AMLEKAKVNM PAKPAPPTKA TSKPMGGSAP AKFQPASAPA EDCISSSTEP KPDPKKAKAP GLSSKAKSAQ GKKMPSKTSL KEDEDKSGPI FIVVPNGKEQ RMKDEKGLKV LKWNFTTPRD EYIEQLKTQM SSCVAKWLQD EMFHSDFQHH NKALAVMVDH LESEKEGVIG CLDLILKWLT LRFFDTNTSV LMKALEYLKL LFTLLSEEEY HLTENEASSF IPYLVVKVGE PKDVIRKDVR AILNRMCLVY PASKMFPFIM EGTKSKNSKQ RAECLEELGC LVESYGMNVC QPTPGKALKE IAVHIGDRDN AVRNAALNTI VTVYNVHGDQ VFKLIGNLSE KDMSMLEERI KRSAKRPSAA PIKQVEEKPQ RAQNISSNAN MLRKGPAEDM SSKLNQARSM SGHPEAAQMV RREFQLDLDE IENDNGTVRC EMPELVQHKL DDIFEPVLIP EPKIRAVSPH FDDMHSNTAS TINFIISQVA SGDINTSIQA LTQIDEVLRQ EDKAEAMSGH IDQFLIATFM QLRLIYNTHM ADEKLEKDEI IKLYSCIIGN MISLFQIESL AREASTGVLK DLMHGLITLM LDSRIEDLEE GQQVIRSVNL LVVKVLEKSD QTNILSALLV LLQDSLLATA SSPKFSELVM KCLWRMVRLL PDTINSINLD RILLDIHIFM KVFPKEKLKQ CKSEFPIRTL KTLLHTLCKL KGPKILDHLT MIDNKNESEL EAHLCRMMKH SMDQTGSKSD KETEKGASRI DEKSSKAKVN DFLAEIFKKI GSKENTKEGL AELYEYKKKY SDADIEPFLK NSSQFFQSYV ERGLRVIEME REGKGRISTS TGISPQMEVT CVPTPTSTVS SIGNTNGEEV GPSVYLERLK ILRQRCGLDN TKQDDRPPLT SLLSKPAVPT VASSTDMLHS KLSQLRESRE QHQHSDLDSN QTHSSGTVTS SSSTANIDDL KKRLERIKSS RK
Explore Cytoskeleton-associated protein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets